Search

Displaying results 4201 - 4210 of 10000 in total
  1. Drug

    Vonicog alfa

    go.drugbank.com/drugs/DB12872
    ApprovedInvestigational

    [A264389] Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.[A264389] … [A264444] Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,[L51274] which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.

  2. Drug

    Sulfoxone

    go.drugbank.com/drugs/DB01145
    Approved

    Sulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.

  3. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair. … It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated.

  4. Drug

    Picric acid

    go.drugbank.com/drugs/DB03651
    Approved

    Used as antiseptic, astringent, and stimulant for epitheliazation.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States … Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections.

  6. Drug

    Coccidioides immitis spherule

    go.drugbank.com/drugs/DB11294
    Approved

    Coccidioides immitis spherule is a skin test antigen indicated to detect delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis.

  7. Drug

    Metixene

    go.drugbank.com/drugs/DB00340
    Approved

    Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.

  8. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.

    Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
  9. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    [L52585,L52590] Previously marketed in Japan, in December 2024 Kostaive became the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission.[L52580,L52585] … Self-amplification allows for the use of lower doses while providing higher immunogenicity compared to a conventional mRNA COVID-19 vaccine.

  10. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation. … DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack.